Physician profile
Alan Greenwald
NPI 1891730065
$5,243.53
in general payments reported to CMS, 2019-2025
29 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,647 · 2020: $12.27 · 2021: $326 · 2022: $377 · 2023: $136 · 2024: $1,501 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $941 · Food and Beverage: $939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $941.18 |
| Food and Beverage | $939.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, Lp | $2,505.93 | 2019 | |
| Stryker Corporation | $1,332.79 | 2019-2024 | Iconix, Inspace |
| Zimmer Biomet Holdings, INC. | $304.73 | 2019-2021 | |
| Amgen INC. | $171.16 | 2021-2025 | |
| Gilead Sciences, INC. | $137.73 | 2023-2024 | |
| Becton, Dickinson and Company | $119.09 | 2025 | Channel Drain |
| Exact Sciences Corporation | $63.34 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $51.88 | 2022-2024 | |
| Ucb, INC. | $49.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $48.86 | 2022 | |
| Xeris Pharmaceuticals, INC. | $47.00 | 2023-2024 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $42.94 | 2021-2022 | |
| Glaxosmithkline, LLC. | $37.25 | 2022-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $36.32 | 2022-2024 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $35.26 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $25.42 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $25.41 | 2024 | Injectafer |
| Urovant Sciences INC | $25.32 | 2022 | |
| Heron Therapeutics, INC. | $24.45 | 2023 | Zynrelef |
| E.R. Squibb & Sons, L.L.C. | $22.42 | 2021 | |
| Alk-Abello, INC | $19.68 | 2024 | Grastek, Odactra, Ragwitek |
| Abbott Laboratories | $18.46 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2023 | Entyvio |
| Alnylam Pharmaceuticals INC. | $14.84 | 2021 | |
| Depuy Synthes Sales INC. | $14.57 | 2019 | |
| Corcept Therapeutics | $14.43 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.13 | 2024 | Strensiq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.18 | 2022 | |
| Phadia US INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Greenwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.